Purpose: To assess the predictive ability of prostate-specific antigen (PSA) velocity (PSAV) and doubling time (PSADT) for biopsy progression and adverse pathology at prostatectomy among men with low-risk prostate cancer enrolled on an active-surveillance program. Methods: We evaluated 290 men who met criteria for active surveillance (ie, PSA density < 0.15 ng/mL/cm(3) and Gleason score < or = 6 with no pattern > or = 4, involving < or = 2 cores with cancer, and < or = 50% involvement of any core by cancer) with two or more serial PSA measurements after diagnosis from 1994 to 2008. Follow-up included twice-yearly digital rectal exam and PSA measurements and yearly surveillance biopsy. Treatment was recommended for biopsy progression (ie, Gleason score > or = 7, or > 2 positive cores, or > 50% core involvement). Sensitivity and specificity of postdiagnostic PSAV and PSADT were explored by using receiver operating characteristic (ROC) analysis. Results: Overall, 188 (65%) men remained on active surveillance, and 102 (35%) developed biopsy progression at a median follow-up of 2.9 years. PSADT was not significantly associated with subsequent adverse biopsy findings (P = .83), and PSAV was marginally significant (P = .06). No PSAV or PSADT cut point had both high sensitivity and specificity (area under the curve, 0.61 and 0.59, respectively) for biopsy progression. In those who eventually underwent radical prostatectomy, PSAV (P = .79) and PSADT (P = .87) were not associated with the presence of unfavorable surgical pathology. Conclusion: Postdiagnostic PSA kinetics do not reliably predict adverse pathology and should not be used to replace annual surveillance biopsy for monitoring men on active surveillance.
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Editorial Comment
This is an important study concluding that postdiagnostic PSA kinetics do not reliably predict adverse pathology and should not be used to replace annual surveillance biopsy for monitoring men on active surveillance. At Johns Hopkins, the criteria for active surveillance are: PSA density < 0.15 ng/mL/cm3, Gleason score ≤ 6 with no pattern 4 or 5, involving ≤ 2 cores with cancer, and ≤ 50% involvement of any core by cancer (1).
At Stanford, the criteria are: Gleason score ≤ 6 with no pattern 4 or 5, one single core with cancer, linear extent of cancer ≤ 3mm, and serum PSA is not considered (2) . It is controversial whether percentage or linear extent is the best measure.
The follow-up included twice-yearly digital rectal exam and PSA measurements and yearly surveillance biopsy. Tretament was recommended for biopsy progression which was considered whenever Gleason score was ≥ 7, > 2 positive cores, or > 50% core involvement. The important finding in Ross et al. study was that PSA double time was not significantly associated with subsequent adverse biopsy findings (p = 0.83) and PSA velocity was marginally significant (p = 0.06).
